Notizie AIOM – anno XVII
Entrectinib Breaks Through With Japanese Approval for NTRK-Positive Tumors
June 18, 2019 - Entrectinib received its first regulatory approval, as Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the drug for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors. The ...Leggi tutto
Quizartinib Receives Japanese Approval in Relapsed/Refractory FLT3+ AML
June 18, 2019 - The Ministry of Health, Labor and Welfare (MHLW) of Japan has approved quizartinib for the treatment of adult patients with relapsed/refractory FTL3-ITD–positive acute myeloid leukemia (AML), as detected by an MHLW-approved assay. The approval of the ...Leggi tutto
FDA Approves Pembrolizumab for Metastatic SCLC
June 18, 2019 - The FDA has granted an accelerated approval to single-agent pembrolizumab for the treatment of patients with metastatic small cell lung cancer (SCLC) who have disease progression on or after platinum-based chemotherapy and ≥1 other prior line of therapy. ...Leggi tutto